Back to search

Poland· PL-100066970

Tinidazolum Polpharma

A tinidazole product containing tinidazolum, registered in Poland by Zakłady Farmaceutyczne POLPHARMA S.A.. The same ATC class is registered in 4 of our 19 countries.

ATC J01XD02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedTinidazolum PolpharmaATCJ01XD02REGISTER NO.PL-100066970PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Tinidazole is registered in 4 of 19 countries.

Countries holding a registration under ATC J01XD02 (tinidazole), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 3 of them publish a price we can compare per daily dose

Tinidazole · ATC J01XD02

4 / 19 countries

  • Belgiumprice
  • Finlandprice
  • Japan
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Tinidazolum
Manufacturer
Zakłady Farmaceutyczne POLPHARMA S.A.
Country
Poland (PL)
ATC code
J01XD02
ATC class
Tinidazole
Defined daily dose
1.5 g, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909990206117
  • gtin
    05909990206124

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

183 interactions on record for tinidazole.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Tinidazole · interactions on record

183 records

  • 1 severe
  • 181 moderate
  • 1 minor

Most severe, free to view

  • AmprenavirJ05AE05severe
  • LonafarnibA16AX20moderate
  • DicoumarolB01AA01moderate
  • WarfarinB01AA03moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Tinidazole in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tinidazole products

Authorised across Europe · EMA

The same active substance is authorised in 6 EEA countries. Names it is sold under:

  • Bulgaria · Тинидазол Актавис
  • Cyprus · Tinirem
  • Spain · Tricolam
  • France · Fasigyne
  • Italy · Trimonase
  • Romania · Tinizol, Tiprogyn

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ae7f33f1-95bc-4e48-b163-14fae350c80f
GET /v1/drugs/ae7f33f1-95bc-4e48-b163-14fae350c80f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "500 mg",
  "packaging": "05909990206117 ¦ Rp ¦ 10065\n4 tabl.\n05909990206124 ¦ Rp ¦ 20907\n16 tabl.",
  "substance": "Tinidazolum 500 mg",
  "common_name": "Tinidazolum",
  "pl_product_id": "100066970",
  "pozwolenie_nr": "02061",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}

See everything about tinidazole.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.